-transparent.png){kind=logo}
Recent animal studies have demonstrated the capacity of high-intensity focused ultrasound (HIFU) to extracorporeally ablate selective tissue targets in the liver without requiring surgical exposure of the liver or insertion of instruments into the liver. The potential value of HIFU as a noninvasive local treatment for human hepatic cancers has attracted considerable interest. This report reviews the current status of HIFU research and sets forth questions for future study.
Related Publications
R Yang, and
N T Sanghvi, and
F J Rescorla, and
K K Kopecky, and
J L Grosfeld
January 1993,
Oncology,
R Yang, and
N T Sanghvi, and
F J Rescorla, and
K K Kopecky, and
J L Grosfeld
March 2005,
BJU international,
R Yang, and
N T Sanghvi, and
F J Rescorla, and
K K Kopecky, and
J L Grosfeld
May 2007,
Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine,
R Yang, and
N T Sanghvi, and
F J Rescorla, and
K K Kopecky, and
J L Grosfeld
May 2007,
BJU international,
R Yang, and
N T Sanghvi, and
F J Rescorla, and
K K Kopecky, and
J L Grosfeld
January 2015,
Hepato-gastroenterology,
R Yang, and
N T Sanghvi, and
F J Rescorla, and
K K Kopecky, and
J L Grosfeld
July 2005,
BJU international,
R Yang, and
N T Sanghvi, and
F J Rescorla, and
K K Kopecky, and
J L Grosfeld
June 2007,
Expert review of anticancer therapy,
R Yang, and
N T Sanghvi, and
F J Rescorla, and
K K Kopecky, and
J L Grosfeld
January 2003,
Zhonghua zhong liu za zhi [Chinese journal of oncology],
R Yang, and
N T Sanghvi, and
F J Rescorla, and
K K Kopecky, and
J L Grosfeld
July 2005,
Breast cancer research and treatment,
R Yang, and
N T Sanghvi, and
F J Rescorla, and
K K Kopecky, and
J L Grosfeld
January 2019,
Journal of cancer research and therapeutics,
